to determine if the observed liver uptake of an 111in-labeled anti-melanoma antibody 96.5 ( 111in-96.5 ) was dependent on the presence of hepatic antigen or on recognition of circulating murine antibody , escalating doses of an unlabeled nonimmunoreactive moab ( nir-moab ) were administered to 18 patients with metastatic malignant melanoma either 1 or 24 h prior to an infusion of 1 mg of 111in-96.5 .
C0003241
antibody
C0003250
moab